How to Get AndroGel in New Hampshire

What Is AndroGel and Why New Hampshire Men Use It

AndroGel is a hydroalcoholic testosterone gel approved by the FDA for adult males with primary or hypogonadotropic hypogonadism, delivering testosterone transdermally once daily to restore serum testosterone to the normal male range of roughly 300, 1 to 000 ng/dL [1]. AbbVie manufactures two concentrations: 1% (delivering 25 mg or 50 mg per packet) and 1.62% (delivering 20.25 mg, 40.5 mg, 60.75 mg, or 81 mg per metered pump actuation or packet).

Testosterone deficiency is common. The European Male Ageing Study found a biochemical hypogonadism prevalence of approximately 17% in men aged 40, 79, rising sharply after age 60 [2]. New Hampshire's median male age is 40.7 years (U.S. Census 2023), meaning a meaningful share of adult men may qualify for evaluation.

The landmark T-Trials (N=788 men, mean age 72) demonstrated that testosterone treatment significantly improved sexual desire, erectile function, and bone mineral density compared with placebo at 12 months [3]. Bone mineral density in the lumbar spine increased by 7.5% (P<0.001) in the testosterone arm versus 0.3% placebo. While the T-Trials used injectable and gel formulations, the data informs prescribing decisions for topical testosterone broadly.

Gel formulations avoid the peak-and-trough serum swings seen with weekly intramuscular injections. A pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism confirmed that AndroGel 1.62% produced steady-state total testosterone within the eugonadal range in 77% of treated men at day 182 [4]. That stability is one reason many New Hampshire prescribers favor gel over injection for patients who prefer to avoid weekly self-injection.

New Hampshire Prescribing Rules for Testosterone Gel

Any licensed prescriber with DEA Schedule III authority may write for AndroGel in New Hampshire. That includes MDs, DOs, nurse practitioners holding full prescriptive authority under NH RSA 326-B, and physician assistants supervised per NH RSA 328-D [5]. New Hampshire grants NPs full practice authority without physician oversight requirements for prescribing, which broadens telehealth access considerably.

Testosterone is a Schedule III controlled substance under the federal Controlled Substances Act [6]. New Hampshire follows federal scheduling. That means every AndroGel prescription must originate from a valid prescriber-patient relationship, defined by the Ryan Haight Act as at least one prior in-person or synchronous audio-video evaluation before a controlled substance can be prescribed via telehealth [7]. Most telehealth platforms serving NH conduct a live video intake visit that satisfies this requirement.

The New Hampshire Board of Medicine and Board of Nursing each publish telehealth practice standards requiring that prescribers document clinical indication, informed consent for treatment, and a plan for follow-up monitoring. A prescription written without documented indication could be flagged by NH's Prescription Drug Monitoring Program (PDMP), which tracks all Schedule III fills statewide [5].

The Endocrine Society's 2018 clinical practice guideline states: "We recommend confirming the diagnosis of androgen deficiency by measuring serum testosterone on at least two separate occasions using a reliable assay before initiating testosterone therapy." [8] New Hampshire insurers cite this guideline verbatim in their prior authorization criteria.

Labs Required Before AndroGel Is Prescribed in New Hampshire

Two fasting morning serum total testosterone measurements are the minimum requirement. Draw timing matters because testosterone peaks between 7 a.m. and 10 a.m. and drops by 30 to 35% by afternoon [9]. A single afternoon draw below the reference range does not by itself confirm hypogonadism.

Standard pre-treatment panel at most NH practices:

• Total testosterone (two separate morning draws, at least one week apart)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• CBC (hematocrit baseline, since testosterone stimulates erythropoiesis)
• PSA (men 40+ or any man with a prostate cancer risk factor) [8]
• Comprehensive metabolic panel
• SHBG and calculated free testosterone when total T is borderline (250 to 400 ng/dL)

The Endocrine Society guideline places the biochemical cutoff for hypogonadism at a total testosterone below 300 ng/dL on a morning draw from a reliable, assay-validated laboratory [8]. Quest Diagnostics and LabCorp both operate patient service centers in Manchester, Concord, Nashua, and Portsmouth, NH, and are in-network with most NH commercial plans [10].

Follow-up labs at three to six months post-initiation include repeat total testosterone (drawn 2 to 8 hours after gel application), hematocrit, and PSA. Hematocrit above 54% warrants dose reduction or temporary discontinuation per FDA labeling [1].

How to Get an AndroGel Prescription Through Telehealth in New Hampshire

Telehealth prescribing of controlled substances in NH is legal provided the prescriber holds a valid NH license and DEA registration, and the patient has completed a synchronous audio-video intake visit [7]. Several national TRT telehealth platforms are licensed in NH, including HealthRX, Defy Medical, and Fountain TRT, though availability changes; always confirm current NH licensure before booking.

The typical telehealth intake process runs as follows. First, the patient completes an online symptom and health-history questionnaire. Second, a lab order is sent electronically to a national lab network; the patient draws blood at a local NH collection site. Third, a prescriber reviews labs and conducts a live video visit, usually 15 to 20 minutes. Fourth, if indicated, an AndroGel prescription is transmitted electronically to a retail pharmacy or licensed 503A compounding pharmacy in NH or with NH shipping authority.

Turnaround from lab draw to first prescription is typically 7 to 14 days, assuming no insurance prior authorization is required. With prior authorization, add 5, 15 business days depending on the insurer.

The American Urological Association's 2018 testosterone deficiency guideline recommends that "patients initiating testosterone therapy should have follow-up laboratory testing at 3 to 6 months and then annually thereafter." [11] Telehealth platforms that serve NH must build this monitoring cadence into their care protocol to comply with the NH Board of Medicine telehealth rules [5].

A 2021 survey published in Translational Andrology and Urology found that 68% of men initiating TRT via telehealth reported equal or greater satisfaction compared with in-person TRT management, largely driven by reduced travel time and same-day lab result access [12].

Retail vs. Compounding Pharmacy Options in New Hampshire

Brand AndroGel (AbbVie) is available at retail pharmacies across NH. CVS, Walgreens, Walmart Pharmacy, and Hannaford Supermarket pharmacies stock or can order AndroGel 1% and 1.62%. GoodRx pricing for AndroGel 1.62% (75 g pump, 30-day supply) ranges from approximately $420 to $590 without insurance in NH ZIP codes as of mid-2025 [13].

Generic testosterone gel 1% (from Perrigo, Taro, and others) costs significantly less. A 150 g tube of testosterone gel 1% through GoodRx runs approximately $90, $160 at NH retail pharmacies [13]. The FDA approved the first generic testosterone 1% gel in 2015, and bioequivalence data confirm comparable pharmacokinetics to brand AndroGel [14].

503A compounding pharmacies are patient-specific pharmacies licensed under state pharmacy law and regulated by state boards rather than FDA manufacturing standards. New Hampshire's Board of Pharmacy licenses 503A compounders that may prepare testosterone gel in concentrations or bases not commercially available (for example, a testosterone 2% gel in a Lipoderm base for patients with skin sensitivity) [15]. A valid prescription from a licensed NH prescriber is required. The compounded product cannot cross state lines commercially, though a patient may legally transport a personal supply.

NH Medicaid does not cover AndroGel for male hypogonadism as of the current preferred drug list [16]. Men on Medicaid may explore generic testosterone gel through manufacturer patient assistance programs. AbbVie's myAbbVie Assist program offers AndroGel at no cost to qualifying uninsured or underinsured patients meeting income thresholds [17].

Insurance Prior Authorization for AndroGel in New Hampshire

Most commercial plans sold through NH's exchange or employer groups require prior authorization (PA) before covering AndroGel or its generics. Anthem BCBS of NH, Harvard Pilgrim Health Care, and Ambetter NH each list testosterone gel under a PA tier on their 2025 formularies [18].

Common PA documentation requirements in NH:

• Two morning total testosterone values below 300 ng/dL, drawn at least one week apart
• ICD-10 diagnosis code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) for secondary hypogonadism
• Clinical notes documenting symptoms consistent with hypogonadism (fatigue, decreased libido, loss of muscle mass)
• PSA result for men 40 and older
• Prescriber attestation that generic testosterone gel was considered or trialed first

PA processing takes 3, 15 business days under NH's Insurance Department rules, which require insurers to respond to non-urgent PA requests within 15 business days [19]. Urgent PA requests tied to acute clinical need must be answered within 72 hours. If the PA is denied, NH law provides a formal appeal process, and the prescriber may request a peer-to-peer review call with the insurer's medical director, which overturns initial denials in approximately 30 to 40% of cases nationally [20].

Transferring an Existing AndroGel Prescription to New Hampshire

Moving to NH with an existing testosterone prescription is straightforward at the pharmacy level. Retail chains like CVS and Walgreens can transfer a controlled-substance prescription from an out-of-state location to an NH store one time, after which the prescription is consumed [21]. Federal law restricts refills on Schedule III substances to five refills within six months of the original date; once those are used or the six months expire, a new prescription is required.

The prescriber relationship is more important than the pharmacy transfer. If your original prescriber is not licensed in NH, you will need a new NH-licensed provider to evaluate you and issue a new prescription. Most telehealth platforms can onboard a transferred patient quickly if you bring prior lab work (within 6 months) and treatment records, potentially skipping the repeat baseline labs.

The DEA does not maintain a public database of which out-of-state prescriptions remain valid in a new state; the responsibility falls on the NH pharmacy to verify the original prescribing state's scheduling rules match NH's Schedule III classification for testosterone [6].

Dosing and Application Guidance for AndroGel in New Hampshire Patients

The FDA-approved starting dose for AndroGel 1.62% is 40.5 mg (two pump actuations) applied once daily to the upper arms and shoulders [1]. Dose is titrated based on morning serum testosterone drawn 2 to 8 hours post-application at day 14 and day 28.

Target range per FDA labeling is 400 to 930 ng/dL at steady state. If testosterone at day 14 is below 400 ng/dL, dose increases to 60.75 mg (three pumps). If above 930 ng/dL, dose decreases to 20.25 mg (one pump). Maximum dose is 81 mg (four pumps) daily [1].

Transfer to female partners or children via skin contact is a real risk. The FDA issued a black-box warning in 2009 after reports of virilization in children who had secondary exposure through skin contact with treated men [1]. NH prescribers are required to counsel patients on hand washing after application, covering the application site with clothing, and avoiding skin-to-skin contact for at least two hours after application [8].

A 2014 analysis in JAMA Internal Medicine examining 544,115 commercial insurance claims found that testosterone prescriptions increased 3-fold between 2001 and 2011, with topical gel accounting for 66% of those prescriptions by 2011 [22]. Prescribing has since been moderated by FDA safety communications, but topical testosterone remains the most commonly dispensed TRT formulation in the United States [14].

Monitoring Safety on AndroGel: What NH Patients Should Know

Testosterone therapy carries well-characterized risks that require ongoing lab surveillance. Polycythemia (hematocrit above 54%) occurs in roughly 5.7% of men on TRT at standard doses and requires dose reduction or temporary cessation [23]. Erythrocytosis risk is lower with transdermal gel than with intramuscular testosterone cypionate, since gel produces smaller hematocrit elevations due to steadier serum levels [24].

Cardiovascular risk has been debated since the TRAVERSE trial (N=5,198 men, mean age 63.3) reported in 2023 that testosterone replacement did not significantly increase major adverse cardiovascular events (MACE) compared with placebo over a median 33 months (hazard ratio 0.96 to 95% CI 0.78, 1.17) [25]. TRAVERSE also found higher rates of atrial fibrillation (3.5% vs. 2.4%, P<0.05) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm, outcomes that NH prescribers discuss during informed consent [25].

Prostate safety data from the T-Trials showed no significant difference in prostate cancer incidence between testosterone and placebo groups at 12 months, though the follow-up was short [3]. The Endocrine Society recommends PSA monitoring at 3 to 6 months, 12 months, and annually thereafter [8].

Fertility suppression is a near-universal effect of exogenous testosterone. Exogenous T suppresses the HPG axis, reducing LH and FSH and halting spermatogenesis in most men within 3 to 4 months of initiation [26]. Men who want to preserve fertility should discuss alternatives such as clomiphene citrate 25 mg every other day or human chorionic gonadotropin (hCG) co-therapy before starting AndroGel [8].

Cost Reduction Strategies for NH Patients

Generic testosterone gel 1% remains the most cost-effective topical testosterone for cash-pay NH patients. At $90, $160 per month at NH retail pharmacies, it is 60 to 75% less expensive than brand AndroGel 1.62% [13]. The clinical outcomes between brand and generic 1% gel are equivalent per FDA bioequivalence standards [14].

Patient assistance programs provide another route. AbbVie's myAbbVie Assist program covers AndroGel at no charge for uninsured patients with household incomes at or below 600% of the federal poverty level [17]. Applications can be submitted online or by phone through AbbVie's dedicated line, with approval typically within 2 to 4 weeks.

GoodRx Gold membership ($9.99/month) reduces generic testosterone gel 1% to as low as $70 at select NH pharmacies. Mark Cuban's Cost Plus Drugs platform lists testosterone gel 1% (Perrigo) at approximately $55 for a 150 g tube, though NH pharmacy availability through that platform varies [13].

503A compounded testosterone gel is almost always less expensive than brand and often less expensive than generic retail. A 30-day supply of compounded testosterone 2% gel from an NH-licensed 503A pharmacy typically runs $60, $120 depending on volume and base used [15]. The trade-off is that compounded products lack FDA-approved manufacturing oversight, and potency and sterility standards vary by compounder.